An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results

Detalles Bibliográficos
Autor principal: Ader, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076583/
https://www.ncbi.nlm.nih.gov/pubmed/35533972
http://dx.doi.org/10.1016/j.cmi.2022.04.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076583/
https://www.ncbi.nlm.nih.gov/pubmed/35533972
http://dx.doi.org/10.1016/j.cmi.2022.04.016

Ejemplares similares